This isnt a failing of the medicines it reflects the nature of obesity as a chronic, relapsing condition, said Dr
A maintenance dose is any dose you choose to stay on long-term to help you support weight loss
The Oral GLP-1 Race: Aleniglipron and Beyond The approval of Foundayo has confirmed the commercial viability of the oral small-molecule GLP-1 category, and competition is intensifying
A review published in 2025 in the Journal of Crohns and Colitis suggests that GLP-1 medications have both metabolic and anti-inflammatory benefits for people with IBD, with early studies linking them to improved outcomes like fewer hospitalizations
Increased risk of erectile dysfunction with semaglutide in non-diabetic obese patients
But as the hype grows, so do the questions: whos using them, what are they saying about their experiences, and how is this trend reshaping the conversation around health and body image in Hollywood